arrow
J

Joaquim Mullol

University of Barcelona
H指数:95
被引数:3.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The First Biosimilar for Biologics in Allergy: CT-P39 (Omlyclo-Omalizumab-Igec) Is Available for Asthma, Chronic Spontaneous Utricaria, and Chronic Rhinosinusitis With Nasal Polyps

首个用于过敏领域的生物类似药:CT-P39(Omlyclo-Omalizumab-Igec)适用于哮喘、慢性自发性荨麻疹和伴有鼻息肉的慢性鼻窦炎

2026-04-250
PRE
Meta-Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force

系统性糖皮质激素在炎症性上呼吸道疾病和哮喘中的危害:EAACI工作组荟萃分析

2026-04-010
PRE
The Unmet Need of Olfactory Testing in Inflammatory Disorders of the Upper Airways—An EAACI Position Paper

上气道炎症性疾病中嗅觉测试的未满足需求——EAACI立场文件

2026-02-020
PRE
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial

Dupilumab与omalizumab在慢性鼻窦炎伴鼻息肉及共存哮喘患者中的比较(EVEREST):一项多中心、随机、双盲、头对头IV期试验

2025-09-280
PRE
Characterization of Chronic Rhinosinusitis Patients Based on Markers of Type 2 Inflammation: Findings From the European CRS Outcome Registry (CHRINOSOR)

基于2型炎症标志物的慢性鼻窦炎患者特征分析:欧洲CRS结局登记研究(CHRINOSOR)的结果

2025-08-310
OAAI
Stability of Asthma Biomarkers Over a Two-year Period Using Three Distinct Classifications in the MEGA Cohort

哮喘生物标志物在两年期间内的稳定性:MEGA队列中三种不同分类的应用

2025-07-050
PRE
The Development and Validation of the Smell-Qx Questionnaire, Based on a Systematic Review of the Literature and the COMET Initiative on the Development of Core Outcome Sets for Clinical Trials in Olfactory Disorders

基于对文献的系统性回顾以及针对嗅觉障碍临床试验核心结局指标集开发的COMET倡议,对Smell-Qx问卷的开发与验证。

2025-05-090
OAAI